Yearly STL Archives: 2022
A novel topical corticosteroid, halobetasol propionate (HP) 0.01% lotion (Bryhali™), has recently been introduced for the treatment of plaque psoriasis and corticosteroid-responsive dermatoses in adults.
This update covers Nivolumab + Relatlimab-rmbw for IV use - Opdualag™ (Bristol-Myers Squibb), Sirolimus topical gel 0.2% - Hyftor™ (Nobelpharma America), Oral epinephrine - AQST-109 (Aquestive Therapeutics), and Bimekizumab for SC use - Bimzelx® (UCB Canada Inc.).
Plerixafor on a WHIM – Promise or Fantasy of a New CXCR4 Inhibitor for This Rare, but Important Syndrome?
Emerging molecular experimental and clinical data suggests that CXCR4 may play an important role in other skin and systemic diseases including mycosis fungoides/Sézary syndrome, neurofibromatosis type 1 tumors, allergic reactions, Waldenström macroglobulinemia, melanoma, non-melanoma skin cancers and other solid tumors.
Transition of Topical Therapy Formulation in Psoriasis: Insights from a Canadian Practice Reflective
The benefits of transitioning from Cal/BD ointment or gel to aerosol foam formulation in this Canadian patient population were similar to those reported in clinical studies and were seen consistently among patients with a range of treatment priorities and with differing history of psoriasis severity and treatment history.
This update covers Adalimumab biosimilar - Yuflyma™ (Celltrion Healthcare), Adalimumab biosimilar - Simlandi™ (Alvotech/JAMP Pharma), Abrocitinib tablet - Cibinqo® (Pfizer), Upadacitinib tablet - Rinvoq® (AbbVie), Risankizumab-rzaa SC injection - Skyrizi® (AbbVie), and HA-based dermal filler - Juvéderm® Volbella® XC (AbbVie/ Allergan Aesthetics).
Clascoterone 1% cream represents a novel and promising therapeutic agent in the management of acne vulgaris for individuals ≥12 years of age. Notably, this topical agent was not observed to have significant systemic effects seen with systemic anti-androgenic agents.
Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications
Currently, JAK inhibitors are only FDA approved for dermatologic, rheumatologic, and hematologic conditions. Recent studies show the utility of JAK inhibitors in treating atopic dermatitis, psoriasis, psoriatic arthritis, vitiligo, and alopecia areata.
Drug update covering: Adalimumab-adbm for SC use - Cyltezo®, Tralokinumab for SC use - Adtralza® (in Canada), Tralokinumab-ldrm for SC use - Adbry™ (in US), Melanoma vaccine for IV use - BNT111, Adalimumab-aqvh for SC use - Yusimry™, and more...
This index covers all articles published in Skin Therapy Letter Dermatology Edition articles in 2021. Articles are indexed by drug names, trade names and disease terms. Bold entries refer to major references.